Spyre Therapeutics, Inc.

NASDAQ:SYRE

Biotechnology

Healthcare
$97.63 +1.38%

+$1.21 today

Market cap
$9.27B
Beta
3.06
P/E (TTM)
-171.1
EPS (TTM)
-$0.52
52W Low $14.00High $91.04

Volume 0.63M

Average 1.17M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$209.56M

FY 2025 · Annual

Net Income

-$155.20M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.74M2.33M886K00
Cost of Revenue0000171.65M
Gross Profit18.74M2.33M886K0(171.65M)
Gross Margin100.0%100.0%100.0%——
Research & Development57.07M58.58M89.5M162.79M171.65M
Selling, General & Admin27.32M28.53M39.95M45.78M47.91M
Operating Expenses84.39M87.11M243.19M208.57M37.91M
Depreciation & Amortization1.58M1.96M744K010M
EBITDA(64.08M)(81.99M)(127.82M)(207.97M)(209.56M)
EBITDA Margin-342.0%-3520.3%-14426.6%——
Operating Income(65.65M)(84.78M)(242.3M)(208.57M)(209.56M)
Operating Margin-350.3%-3640.2%-27348.0%——
Interest Income111K837K6.15M21.31M24.89M
Interest Expense00000
Other Income / Expenses(11K)830K(96.51M)599K54.34M
Income Before Tax(65.66M)(83.95M)(338.82M)(207.97M)(155.22M)
Pre-Tax Margin-350.4%-3604.6%-38241.1%——
Income Tax Expense141K(136K)(26K)51K(15K)
Net Income(65.8M)(83.82M)(338.79M)(208.02M)(155.2M)
Net Margin-351.1%-3598.8%-38238.1%——
EPS (Basic)(25.02)(24.86)(46.15)(3.18)(1.98)
EPS (Diluted)(25.02)(24.86)(46.15)(3.18)(1.98)
Weighted Avg Shares2.63M3.37M6.9M47.03M64.06M
Weighted Avg Shares (Diluted)2.63M3.37M6.9M47.03M64.06M

SYRE Earnings Waterfall · TTM

NASDAQ:SYRE · Revenue to Net Income

Key Ratios

EPS$-2.74
Gross Margin12.5%
Net Margin-17.3%
P/E Ratio-28.5
P/S Ratio6.8

Analysis

$90.5M of revenue converted into -$263.9M of net income for the selected period. Gross margin is 12.5% and net margin is -17.3%, showing how much revenue survives after costs and taxes. EPS is $-2.74, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 3, 2026
8-KCurrent reportNov 3, 2026
SC 13D/ASC 13D/A filingOct 9, 2026
8-KCurrent reportOct 7, 2026
424B5424B5 filingOct 6, 2026

How much revenue does SYRE generate?

Spyre Therapeutics, Inc. (SYRE) reported $0.00 of revenue in fiscal 2025.

Is SYRE profitable?

Spyre Therapeutics, Inc. (SYRE) reported -$155.20M of net income.